Clinical Research

A new option for EPI
By DDN Staff

A new option for EPI

AzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 4 • April 2021

April 2021

April 2021 issue